After a decade studying woodland caribou on Fogo Island, N.L., Allegra Love noticed something she had never witnessed: a pregnant female growing new antlers in early spring.

-- Long-term durability observed for CB-010 allogeneic cell therapy at dose level 1 in ANTLER trial for r/r B-NHL -- -- ANTLER trial enrolling patients at dose level 3 -- 6 of 6 patients achieved a ...

Caribou Biosciences shows promise with a 94% overall response rate in Phase 1 trials for CB-010, but faces a competitive CAR-T landscape. Financially robust with $292.5M liquid assets, but concerns ...

-- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 -- -- CB-011 CaMMouflage Phase 1 ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...